Nickel-induced cell death and survival pathways in cultured renal proximal tubule cells: roles of reactive oxygen species, ceramide and ABCB1.

Archives of toxicology 20140401

Optimization of irinotecan chronotherapy with P-glycoprotein inhibition.

Toxicology and applied pharmacology 20140201

Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

Journal of medicinal chemistry 20120524

Encapsulation of P-glycoprotein inhibitors by polymeric micelles can reduce their pharmacokinetic interactions with doxorubicin.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20120501

Oral and inhaled corticosteroids: differences in P-glycoprotein (ABCB1) mediated efflux.

Toxicology and applied pharmacology 20120501

Circadian variations in exsorptive transport: in situ intestinal perfusion data and in vivo relevance.

Chronobiology international 20120501

Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein.

Journal of medicinal chemistry 20120412

Cerebrospinal fluid can be used as a surrogate to assess brain exposures of breast cancer resistance protein and P-glycoprotein substrates.

Drug metabolism and disposition: the biological fate of chemicals 20120401

Amine linked flavonoid dimers as modulators for P-glycoprotein-based multidrug resistance: structure-activity relationship and mechanism of modulation.

Journal of medicinal chemistry 20120308

Co-delivery of doxorubicin and PSC 833 (Valspodar) by stealth nanoliposomes for efficient overcoming of multidrug resistance.

Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 20120101

Identification and characterization of ABCB1-mediated and non-apoptotic sebum secretion in differentiated hamster sebocytes.

Biochimica et biophysica acta 20111201

Quinidine as an ABCB1 probe for testing drug interactions at the blood-brain barrier: an in vitro in vivo correlation study.

Journal of biomolecular screening 20110901

Synthesis and structure-activity evaluation of isatin-β-thiosemicarbazones with improved selective activity toward multidrug-resistant cells expressing P-glycoprotein.

Journal of medicinal chemistry 20110825

Differentiated human colorectal cancer cells protect tumor-initiating cells from irinotecan.

Gastroenterology 20110701

ABCB1 protects kidney proximal tubule cells against cadmium-induced apoptosis: roles of cadmium and ceramide transport.

Toxicological sciences : an official journal of the Society of Toxicology 20110601

P-glycoprotein modulation by valspodar and cyclosporin does not increase tumor uptake of doxorubicin administered via isolated lung perfusion to rats bearing sarcoma lung metastases.

Anticancer research 20110601

Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells.

Oncology reports 20110401

P-glycoprotein is functionally expressed in the placenta-derived bovine caruncular epithelial cell line 1 (BCEC-1).

Placenta 20110201

Regional absorption of fexofenadine in rat intestine.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20101223

Induction of CYP3A4 by vinblastine: Role of the nuclear receptor NR1I2.

The Annals of pharmacotherapy 20101101

P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.

Blood 20100902

P-glycoprotein inhibition potentiates the behavioural and neurochemical actions of risperidone in rats.

The international journal of neuropsychopharmacology 20100901

Interaction of anthelmintic drugs with P-glycoprotein in recombinant LLC-PK1-mdr1a cells.

Chemico-biological interactions 20100805

Development of a polymeric micellar formulation for valspodar and assessment of its pharmacokinetics in rat.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20100601

Phase I study of valspodar (PSC-833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: a report from the Children's Oncology Group.

Pediatric blood & cancer 20100501

Absorption barriers in the rat intestinal mucosa: 2. Application of physiologically based mathematical models to quantify mechanisms of drug permeation and metabolism.

Journal of pharmaceutical sciences 20100201

Synergistic influence of Abcb1 and Abcc2 on disposition and sterol lowering effects of ezetimibe in rats.

Journal of pharmaceutical sciences 20100101

Pharmacokinetics of PSC 833 (valspodar) in its Cremophor EL formulation in rat.

Xenobiotica; the fate of foreign compounds in biological systems 20100101

Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.

British journal of pharmacology 20091001

Influence of melanosome dynamics on melanoma drug sensitivity.

Journal of the National Cancer Institute 20090916

Dynamic assessment of mitoxantrone resistance and modulation of multidrug resistance by valspodar (PSC833) in multidrug resistance human cancer cells.

The Journal of pharmacology and experimental therapeutics 20090801

CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma.

British journal of haematology 20090601

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34+ cells to imatinib.

Experimental hematology 20090601

The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.

British journal of haematology 20090501

P-glycoprotein versus MRP1 on transport kinetics of cationic lipophilic substrates: a comparative study using [99mTc]sestamibi and [99mTc]tetrofosmin.

Cancer biotherapy & radiopharmaceuticals 20090401

Up-regulation of P-glycoprotein by HIV protease inhibitors in a human brain microvessel endothelial cell line.

Journal of neuroscience research 20090301

Development and characterisation of a new model of rat trophoblasts.

Toxicology in vitro : an international journal published in association with BIBRA 20090201

Clearance and clearance inhibition of the HIV-1 protease inhibitors ritonavir and saquinavir in sandwich-cultured rat hepatocytes and rat microsomes.

Toxicology in vitro : an international journal published in association with BIBRA 20090201

The role of P-glycoprotein in intestinal transport versus the BBB transport of tetraphenylphosphonium.

Molecular pharmaceutics 20090101

The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors.

BMC cancer 20090101

Characterization of substrates and inhibitors for the in vitro assessment of Bcrp mediated drug-drug interactions.

Pharmaceutical research 20081001

pH dependent efflux of methamphetamine derivatives and their reversal through human Caco-2 cell monolayers.

European journal of pharmacology 20080911

P-glycoprotein down-regulates expression of breast cancer resistance protein in a drug-free state.

FEBS letters 20080723

Development of a liquid chromatography-mass spectrometry (LC/MS) assay method for the quantification of PSC 833 (Valspodar) in rat plasma.

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20080615

Modulation of Na+-Ca2+ exchanger expression by immunosuppressive drugs is isoform-specific.

Molecular pharmacology 20080401

Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1((R)).

Biochemical pharmacology 20080315

Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.

European journal of pharmacology 20080114

Quantitation of doxorubicin uptake, efflux, and modulation of multidrug resistance (MDR) in MDR human cancer cells.

The Journal of pharmacology and experimental therapeutics 20080101

Epigenetic mechanisms involved in differential MDR1 mRNA expression between gastric and colon cancer cell lines and rationales for clinical chemotherapy.

BMC gastroenterology 20080101

(99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors.

International journal of cancer 20071215

Placental transfer of quetiapine in relation to P-glycoprotein activity.

Journal of psychopharmacology (Oxford, England) 20070901

Modulation of the brain distribution of imatinib and its metabolites in mice by valspodar, zosuquidar and elacridar.

Pharmaceutical research 20070901

Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier.

Journal of neurochemistry 20070901

Dose finding study of oral PSC 833 combined with weekly intravenous etoposide in children with relapsed or refractory solid tumours.

European journal of cancer (Oxford, England : 1990) 20070901

DNA damage caused by benzo(a)pyrene in MCF-7 cells is increased by verapamil, probenecid and PSC833.

Toxicology letters 20070227

Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.

Neuropharmacology 20070201

Danofloxacin-mesylate is a substrate for ATP-dependent efflux transporters.

British journal of pharmacology 20070201

Celecoxib enhances doxorubicin-induced cytotoxicity in MDA-MB231 cells by NF-kappaB-mediated increase of intracellular doxorubicin accumulation.

European journal of cancer (Oxford, England : 1990) 20070101

Interaction of macrocyclic lactones with P-glycoprotein: structure-affinity relationship.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20070101

Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein.

Psychopharmacology 20060901

Role of P-glycoprotein in cyclosporine cytotoxicity in the cyclosporine-sirolimus interaction.

Kidney international 20060901

Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.

Current opinion in pharmacology 20060801

Role of P-glycoprotein in tissue uptake of indinavir in rat.

Life sciences 20060801

Progesterone regulation of the expression and function of multidrug resistance type I in porcine granulosa cells.

Reproductive toxicology (Elmsford, N.Y.) 20060701

The sea urchin embryo as a model for studying efflux transporters: roles and energy cost.

Marine environmental research 20060701

Efavirenz does not interact with the ABCB1 transporter at the blood-brain barrier.

Pharmaceutical research 20060701

Characterization of beta-adrenoceptor antagonists as substrates and inhibitors of the drug transporter P-glycoprotein.

Fundamental & clinical pharmacology 20060601

Multidrug resistance and stem cells in acute myeloid leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research 20060601

ABCB1 modulation does not circumvent drug extrusion from primitive leukemic progenitor cells and may preferentially target residual normal cells in acute myelogenous leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research 20060601

Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer.

Cancer research 20060501

Cyclooxygenase-2 rescues rat mesangial cells from apoptosis induced by adriamycin via upregulation of multidrug resistance protein 1 (P-glycoprotein).

Journal of the American Society of Nephrology : JASN 20060401

Effect of organophosphate pesticide diazinon on expression and activity of intestinal P-glycoprotein.

Toxicology letters 20060301

Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors.

International journal of oncology 20060301

Up-regulation of MDR1 and induction of doxorubicin resistance by histone deacetylase inhibitor depsipeptide (FK228) and ATRA in acute promyelocytic leukemia cells.

Blood 20060215

Phase III study of PSC-833 (valspodar) in combination with vincristine, doxorubicin, and dexamethasone (valspodar/VAD) versus VAD alone in patients with recurring or refractory multiple myeloma (E1A95): a trial of the Eastern Cooperative Oncology Group.

Cancer 20060215

Interactions between the dopamine agonist, bromocriptine and the efflux protein, P-glycoprotein at the blood-brain barrier in the mouse.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20060201

In vivo evaluation of P-glycoprotein function at the blood-brain barrier in nonhuman primates using [11C]verapamil.

The Journal of pharmacology and experimental therapeutics 20060201

Myricetin stimulates the absorption of the pro-carcinogen PhIP.

Cancer letters 20060108

PSC 833, an inhibitor of P-glycoprotein inhibits 1,2-dimethylhydrazine-induced colorectal carcinogenesis in male Fischer F344 rats.

Anticancer research 20060101

Inhibition of P-glycoprotein-mediated transport by extracts of and monoterpenoids contained in Zanthoxyli fructus.

Toxicology and applied pharmacology 20051201

The molecular mechanisms responsible for resistance to ET-743 (Trabectidin; Yondelis) in the Ewing's sarcoma cell line, TC-71.

International journal of oncology 20051201

The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.

Blood 20051015

Immunosuppressors and reversion of multidrug-resistance.

Critical reviews in oncology/hematology 20051001

Imaging recognition of inhibition of multidrug resistance in human breast cancer xenografts using 99mTc-labeled sestamibi and tetrofosmin.

Nuclear medicine and biology 20050801

Functional role of P-glycoprotein in the human blood-placental barrier.

Clinical pharmacology and therapeutics 20050801

Phase I study of pegylated liposomal doxorubicin and the multidrug-resistance modulator, valspodar.

British journal of cancer 20050711

Oxycodone pharmacokinetics and pharmacodynamics in the rat in the presence of the P-glycoprotein inhibitor PSC833.

Journal of pharmaceutical sciences 20050501

Inhibitors of hyaluronan export prevent proteoglycan loss from osteoarthritic cartilage.

The Journal of rheumatology 20050401

Cyclosporin A is a broad-spectrum multidrug resistance modulator.

Clinical cancer research : an official journal of the American Association for Cancer Research 20050315

A phase I and pharmacologic study of idarubicin, cytarabine, etoposide, and the multidrug resistance protein (MDR1/Pgp) inhibitor PSC-833 in patients with refractory leukemia.

Leukemia research 20050301

Cyclosporin a inhibits calcineurin/nuclear factor of activated T-cells signaling and induces apoptosis in retinoblastoma cells.

Investigative ophthalmology & visual science 20050301

Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein.

Naunyn-Schmiedeberg's archives of pharmacology 20050301

Reversal of multidrug-resistance using Valspodar (PSC 833) and doxorubicin in osteosarcoma.

Oncology reports 20041101

Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20041101

Inhibition of hyaluronan export from human fibroblasts by inhibitors of multidrug resistance transporters.

Biochemical pharmacology 20041001

Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.

Investigational new drugs 20040801

In situ transport of vinblastine and selected P-glycoprotein substrates: implications for drug-drug interactions at the mouse blood-brain barrier.

Pharmaceutical research 20040801

ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages.

Antiviral therapy 20040801

A phase I/II study of infusional vinblastine with the P-glycoprotein antagonist valspodar (PSC 833) in renal cell carcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research 20040715

Broad-spectrum modulation of ATP-binding cassette transport proteins by the taxane derivatives ortataxel (IDN-5109, BAY 59-8862) and tRA96023.

Cancer chemotherapy and pharmacology 20040501

Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.

European journal of cancer (Oxford, England : 1990) 20040501

pH dependent uptake of loperamide across the gastrointestinal tract: an in vitro study.

Drug development and industrial pharmacy 20040501

Resistance to microtubule-targeted cytotoxins in a K562 leukemia cell variant associated with altered tubulin expression and polymerization.

Bulletin du cancer 20040501

P-glycoprotein increases the efflux of the androgen dihydrotestosterone and reduces androgen responsive gene activity in prostate tumor cells.

The Prostate 20040401

Distinct groups of multidrug resistance modulating agents are distinguished by competition of P-glycoprotein-specific antibodies.

Biochemical and biophysical research communications 20040319

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20040315

Effect of PSC 833, an inhibitor of P-glycoprotein on N-methyl-N-nitrosourea induced mammary carcinogenesis in rats.

Carcinogenesis 20040301

Effect of PSC 833, an inhibitor of P-glycoprotein, on 1,2-dimethylhydrazine-induced liver carcinogenesis in rats.

Carcinogenesis 20031201

Potential roles of P-gp and calcium channels in loperamide and diphenoxylate transport.

Toxicology and applied pharmacology 20031115

The role of breast cancer resistance protein in acute lymphoblastic leukemia.

Clinical cancer research : an official journal of the American Association for Cancer Research 20031101

In vivo saturation of the transport of vinblastine and colchicine by P-glycoprotein at the rat blood-brain barrier.

Pharmaceutical research 20031001

Application of compartmental modeling to an examination of in vitro intestinal permeability data: assessing the impact of tissue uptake, P-glycoprotein, and CYP3A.

Drug metabolism and disposition: the biological fate of chemicals 20030901

Source of a micro-nutrient in a semi-synthetic basal diet as a causative factor in inducing urinary calculi in rats and its inhibition by PSC 833, a potent inhibitor of P-glycoprotein.

Comparative medicine 20030801

Effect of PSC 833, a potent inhibitor of P-glycoprotein, on the growth of astrocytoma cells in vitro.

Cancer letters 20030730

Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.

Clinical cancer research : an official journal of the American Association for Cancer Research 20030701

Examination of the functional activity of P-glycoprotein in the rat placental barrier using rhodamine 123.

The Journal of pharmacology and experimental therapeutics 20030601

Screening of Tanzanian plant extracts for their potential inhibitory effect on P-glycoprotein mediated efflux.

Phytotherapy research : PTR 20030501

A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.

Leukemia research 20030401

Evaluation of P-glycoprotein-mediated renal drug interactions in an MDR1-MDCK model.

Pharmacotherapy 20030401

MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models.

Blood 20030315

Combined treatment of Bcl-2 antisense oligodeoxynucleotides (G3139), p-glycoprotein inhibitor (PSC833), and sterically stabilized liposomal doxorubicin suppresses growth of drug-resistant growth of drug-resistant breast cancer in severely combined immunodeficient mice.

Journal of experimental therapeutics & oncology 20030101

Modulation of resistance to idarubicin by the cyclosporin PSC 833 (valspodar) in multidrug-resistant cells.

Journal of experimental therapeutics & oncology 20030101

The cyclosporin PSC 833 increases survival and delays engraftment of human multidrug-resistant leukemia cells in xenotransplanted NOD-SCID mice.

Leukemia 20021201

MDR1 modulators improve the chemotherapy response of human hepatoblastoma to doxorubicin in vitro.

Journal of pediatric surgery 20021101

Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.

The Journal of clinical investigation 20021101

Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein.

Journal of neurochemistry 20021001

Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.

Clinical cancer research : an official journal of the American Association for Cancer Research 20020901

Chronic arsenic-exposed human prostate epithelial cells exhibit stable arsenic tolerance: mechanistic implications of altered cellular glutathione and glutathione S-transferase.

Toxicology and applied pharmacology 20020901

Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.

Blood 20020815

Elevated uptake of low density lipoprotein by drug resistant human leukemic cell lines.

Biochemical pharmacology 20020615

Analysis of methotrexate and folate transport by multidrug resistance protein 4 (ABCC4): MRP4 is a component of the methotrexate efflux system.

Cancer research 20020601

P-glycoprotein in acute myeloid leukaemia: therapeutic implications of its association with both a multidrug-resistant and an apoptosis-resistant phenotype.

Leukemia & lymphoma 20020601

Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers.

Leukemia 20020501

The influence of P-glycoprotein on morphine transport in Caco-2 cells. Comparison with paclitaxel.

European journal of pharmacology 20020405

P-glycoprotein inhibition by the multidrug resistance-reversing agent MS-209 enhances bioavailability and antitumor efficacy of orally administered paclitaxel.

Cancer chemotherapy and pharmacology 20020401

Stereoselective transport of hydrophilic quaternary drugs by human MDR1 and rat Mdr1b P-glycoproteins.

British journal of pharmacology 20020401

Enhancement of leukemia rejection by mice successfully treated for L1210 leukemia due to low dose compared to high dose VP-16.

Leukemia research 20020201

Transport activity and surface expression of the Na+-Ca2+ exchanger NCX1 are inhibited by the immunosuppressive agent cyclosporin A and by the nonimmunosuppressive agent PSC833.

The Journal of biological chemistry 20020125

Xenobiotic efflux pumps in isolated fish brain capillaries.

American journal of physiology. Regulatory, integrative and comparative physiology 20020101

[Reversal of multidrug-resistance in human leukemia cell line K562/A02 by a cyclosporin D analogue PSC 833].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 20020101

Evidence of P-glycoprotein mediated apical to basolateral transport of flunisolide in human broncho-tracheal epithelial cells (Calu-3).

British journal of pharmacology 20011201

Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin.

Pharmaceutical research 20011101

Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport.

Cancer research 20011001

In vitro prevention of the emergence of multidrug resistance in a pediatric rhabdomyosarcoma cell line.

Clinical cancer research : an official journal of the American Association for Cancer Research 20011001

Intracellular levels of two cyclosporin derivatives valspodar (PSC 833) and cyclosporin a closely associated with multidrug resistance-modulating activity in sublines of human colorectal adenocarcinoma HCT-15.

Japanese journal of cancer research : Gann 20011001

Effect of PSC 833 liposomes and Intralipid on the transport of epirubicin in Caco-2 cells and rat intestines.

Journal of controlled release : official journal of the Controlled Release Society 20010911

Cross-resistance to cytosine arabinoside in a multidrug-resistant human promyelocytic cell line selected for resistance to doxorubicin: implications for combination chemotherapy.

British journal of haematology 20010901

Overexpression of glutathione S-transferase II and multidrug resistance transport proteins is associated with acquired tolerance to inorganic arsenic.

Molecular pharmacology 20010801

Multidrug-resistance P-glycoprotein (MDR1) secretes platelet-activating factor.

The Biochemical journal 20010801

Effects of the novel cyclosporine derivative PSC833 on glucose metabolism in rat primary cultures of neuronal and glial cells.

Biochemical pharmacology 20010701

Induction of apoptosis in MDR1 expressing cells by daunorubicin with combinations of suboptimal concentrations of P-glycoprotein modulators.

Cancer letters 20010626

The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.

Clinical cancer research : an official journal of the American Association for Cancer Research 20010601

Treatment with inhibitors of caspases, that are substrates of drug transporters, selectively permits chemotherapy-induced apoptosis in multidrug-resistant cells but protects normal cells.

Leukemia 20010601

A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance.

Clinical cancer research : an official journal of the American Association for Cancer Research 20010501

Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia.

Leukemia 20010501

Oral delivery of taxanes.

Investigational new drugs 20010501

Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562.

British journal of cancer 20010401

Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010315

Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood--brain barrier.

AIDS (London, England) 20010309

P-glycoprotein-mediated transport of digitoxin, alpha-methyldigoxin and beta-acetyldigoxin.

Naunyn-Schmiedeberg's archives of pharmacology 20010301

Phase I study of intravenous PSC-833 and doxorubicin: reversal of multidrug resistance.

Japanese journal of cancer research : Gann 20010201

Screening of multidrug-resistance sensitive drugs by in situ brain perfusion in P-glycoprotein-deficient mice.

Pharmaceutical research 20010201

In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.

Cancer research 20010115

Modulator activity of PSC 833 and cyclosporin-A in vincristine and doxorubicin-selected multidrug resistant murine leukemic cells.

Leukemia research 20010101

A reexamination of PSC 833 (Valspodar) as a cytotoxic agent and in combination with anticancer agents.

Cancer chemotherapy and pharmacology 20010101

Selective susceptibility of transformed T lymphocytes to induction of apoptosis by PSC 833, an inhibitor of P-glycoprotein.

Oncology research 20010101

Functional and histochemical analysis of MDR3 P-glycoprotein in a tetracycline-controlled gene expression system.

European journal of medical research 20001229

Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethy lpentanamide and P-glycoprotein by valspodar in gene transfectant systems.

Drug metabolism and disposition: the biological fate of chemicals 20001001

Decreased cortisol secretion by adrenal glands perfused with the P-glycoprotein inhibitor valspodar and mitotane or doxorubicin.

Anti-cancer drugs 20000401

Up-regulation of multidrug resistance P-glycoprotein via nuclear factor-kappaB activation protects kidney proximal tubule cells from cadmium- and reactive oxygen species-induced apoptosis.

The Journal of biological chemistry 20000121

Effect of multidrug resistance-reversing agents on transporting activity of human canalicular multispecific organic anion transporter.

Molecular pharmacology 19991201

Expression of the apical conjugate export pump, Mrp2, in the polarized hepatoma cell line, WIF-B.

Hepatology (Baltimore, Md.) 19981101

Cyclosporin analogs inhibit in vitro growth of Cryptosporidium parvum.

Antimicrobial agents and chemotherapy 19980401

Characterization of anti-Toxoplasma activity of SDZ 215-918, a cyclosporin derivative lacking immunosuppressive and peptidyl-prolyl-isomerase-inhibiting activity: possible role of a P glycoprotein in Toxoplasma physiology.

Antimicrobial agents and chemotherapy 19970901

A patient with adrenocortical carcinoma: characterization of its biological activity and drug resistance profile.

Clinical cancer research : an official journal of the American Association for Cancer Research 19970301

The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates.

The Journal of biological chemistry 19941111

Cholestasis caused by inhibition of the adenosine triphosphate-dependent bile salt transport in rat liver.

Gastroenterology 19940701

Temperature adaptation at the hemoglobin level in Carassius auratus.

Comparative biochemistry and physiology. A, Comparative physiology 19751201